Medad Holding subsidiary, Medad Technology, a leading HealthTech company in the UAE, has recently been granted 331 patents as a result of increased investment in research and development. The company has announced a $150 million investment in R&D, product development, and manufacturing, focusing on Consumer HealthTech, Pharmaceutical HealthTech, and Power Management. This has resulted in an impressive portfolio of patents and proprietary chips that have positioned Medad Technology as a major contributor to innovation in public health.
In 2022, Medad Technology accounted for 39% of all patents originating from the UAE at the World Intellectual Property Organization (WIPO), ranking third after Khalifa University and Abu Dhabi Oil Company. By developing advanced proprietary electronics and algorithms, Medad has optimized aerosol delivery, power management, and operational precision. The innovative chipset has the potential to revolutionize power management beyond inhalation, with applications across the semiconductor industry, highlighting Medad Technology’s commitment to pushing the boundaries of public health innovation.
Mohammed Alshaiba Almazrouei, President of Medad Technology, emphasized the company’s dedication to improving patient outcomes through novel therapeutic solutions and proprietary technologies. The recent clinical study on Medad Technology’s ultrasonic delivery system showcased remarkable efficiency in drug delivery by controlling aerosol particle size, facilitating direct delivery to the deepest regions of the lungs. This breakthrough has the potential to transform pharmaceutical practices by enhancing drug delivery efficiency, preventing and treating chronic illnesses, and enabling the inhalation of medications previously limited to oral administration.
A primary focus of Medad Technology is the evaluation of its technology as a nicotine replacement therapy to aid smoking cessation, offering a promising solution to combat tobacco smoking, a leading cause of preventable death globally. Additionally, the company is working on innovative drug delivery methods to treat diseases like pulmonary hypertension, aiming to reduce side effects associated with traditional pill-based medications. By providing more effective and patient-friendly treatment options, Medad Technology is contributing to the advancement of healthcare solutions that cater to the evolving needs of the global population.
Overall, Medad Technology’s commitment to innovation and dedication to improving public health outcomes have positioned the company as a key player in the HealthTech industry. Through its investment in R&D, product development, and manufacturing, Medad Technology continues to set new standards in drug delivery efficiency, chronic illness prevention, and treatment options. With a strong focus on developing proprietary technologies and advancing public health solutions, Medad Technology is poised to make significant contributions to the healthcare sector, both nationally and internationally.
